NewsBabesiosisMay 27, 2026
60 Degrees Pharmaceuticals Initiates Clinical Trial for Tafenoquine in Babesiosis Patients
60 Degrees Pharmaceuticals has announced the early enrollment of its first seasonal patient in a clinical trial for Tafenoquine aimed at treating Babesiosis. This development could have significant implications for the pharmaceutical landscape.
Dr. Yuki Tanaka
